Table 1.1.3Type III monitors vs. PSG: study results

Study
PMID
Index Test (vs. PSG)NSettingBland-AltmanROC AnalysisQuality
MetricResult, events/hrThreshold, events/hrSensitivity, % (95% CI)Specificity, % (95% CI)AUC
IndexPSG
Garcia-Diaz, 200766
17356086
Respiratory Polygraph – Apnoescreen II in Lab (Obs A)62Sleep lab (& home)95% LOA2.8 (−18, 23)RDI≥10AHI≥1094.6 (87.3, 100)96 (88.3, 100)0.977A
RDI≥15AHI≥1510096.7 (90.2, 100)0.998
RDI≥30AHI≥3095.8 (87.8, 100)94.7 (87.6, 100)0.986
Respiratory Polygraph – Apnoescreen II in Lab (Obs B)1.03 (−19, 21)RDI≥10AHI≥1094.6 (87.3, 100)88 (75.2, 100)0.974
RDI≥15AHI≥1510096.7 (90.2, 100)0.997
RDI≥30AHI≥3095.8 (87.8, 100)94.7 (87.6, 100)0.987
Respiratory Polygraph – Apnoescreen II at Home (Obs A)3.1 (−30, 36)RDI≥10AHI≥1086.4 (75.4, 97.5)1000.969
RDI≥15AHI≥1587.5 (76, 98.9)96.7 (90.2, 100)0.972
RDI≥30AHI≥3091.7 (80.6, 100)94.7 (87.6, 100)0.986
Respiratory Polygraph – Apnoescreen II at Home (Obs B)1.6 (−31, 34)RDI≥10AHI≥1083.8 (71.9, 95.6)92 (81.3, 100)0.976
RDI≥15AHI≥1584.4 (71.8, 96.9)96.7 (90.2, 100)0.977
RDI≥30AHI≥3095.8 (87.8, 100)94.7 (87.6, 100)0.985
Amir, 201070
20191939
Morpheus Hx (bedside computerized analysis system) vs PSG53Sleep Lab95% CI−0.06 (−14.3, 14.2)≥5≥597.2 (nd)94.1 (nd)A
≥15≥15100 (nd)92.7 (nd)
Santos-Silva, 200967
19480230
STD at-home vs. PSG in-lab80Sleep Lab & Home95% LOA−0.7 (−24, 22.6)≥5≥593 (nd)59 (nd)0.90A
≥15≥1585 (nd)80 (nd)0.92
≥30≥3077 (nd)93 (nd)0.95
STD in-lab (done with PSG) vs. PSG in-lab−4.0 (−26.6, 18.6)≥5≥592 (nd)48 (nd)0.91
≥15≥1594 (nd)71 (nd)0.93
≥30≥3086 (nd)79 (nd)0.95
STD at-home vs. PSG in-lab (done with STD)1.6 (−22.2, 25.4)≥5≥595 (nd)62 (nd)0.95
≥15≥1586 (nd)78 (nd)0.95
≥30≥3074 (nd)96 (nd)0.96
STD in-lab (done with PSG) vs. PSG in-lab (done with STD)−1.1 (−24.9, 22.8)≥5≥598 (nd)62 (nd)0.97
≥15≥1597 (nd)74 (nd)0.98
≥30≥3096 (nd)92 (nd)0.98
Ng, 201071
20199644
Embletta portable diagnostic system vs PSG80Sleep lab95% CI1.0 (−7, 8.6) **≥5≥592.4 (nd)85.7 (nd)0.948B
≥10≥1090 (nd)86.7 (nd)0.975
≥15≥1587.8 (nd)94.9 (nd)0.985
≥20≥2085.3 (nd)95.7 (nd)0.984
Planès, 201072
19533191
Type III device (CID102L8) vs Type II PSG (extended version of CID102L8)45Sleep lab95% CI−3.4 (−18.4, 11.6) **≥5≥595 (82, 99)67 (12, 98)B
≥15≥1571 (52, 85)93 (64, 100)
≥30≥3075 (43, 93)97 (82, 100)
To, 200968
19210658
ARES Unicorder vs. PSG141HospitalndData not interpretable from figure≥5 at 4%
O2 desat
≥584 (77, 90)1000.96B
≥5 at 3%
O2 desat
≥589 (84, 94)1000.97
≥5 at 1%
O2 desat
≥597 (94, 99)63 (55, 71)0.98
Tonelli de Oliveira, 200969
19201709
Somnocheck-lab vs. PSG149Sleep lab & Home95% LOA2.6 (−17.7, 22.8)B
Somnocheck-Home vs. PSG3.2(−28, 34.3)≥7AHI≥596.15 (92.5, 99.8)64.7 (42.0, 87.4)0.96
≥9AHI≥1090.7 (82.7, 95.2)82.9 (67.3, 91.9)0.92
≥9AHI≥1581.3 (71.1, 88.5)88.4 (78.8, 94.0)0.91
≥33AHI≥3080 (68.3, 91.7)92.1 (86, 98.2)0.92

From: Appendix D, Summary Tables

Cover of Diagnosis and Treatment of Obstructive Sleep Apnea in Adults
Diagnosis and Treatment of Obstructive Sleep Apnea in Adults [Internet].
Comparative Effectiveness Reviews, No. 32.
Balk EM, Moorthy D, Obadan NO, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.